{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T03:41:57Z","timestamp":1773891717391,"version":"3.50.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T00:00:00Z","timestamp":1794614400000},"content-version":"am","delay-in-days":348,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["OD011132"],"award-info":[{"award-number":["OD011132"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["NS126924"],"award-info":[{"award-number":["NS126924"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["1F31NS124269-01"],"award-info":[{"award-number":["1F31NS124269-01"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["NS045962"],"award-info":[{"award-number":["NS045962"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["NS125502"],"award-info":[{"award-number":["NS125502"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019510","name":"Omeros Corporation","doi-asserted-by":"publisher","award":["OMS-401"],"award-info":[{"award-number":["OMS-401"]}],"id":[{"id":"10.13039\/100019510","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jpet.2025.103760","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T00:58:24Z","timestamp":1761353904000},"page":"103760","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Phosphodiesterase 7 inhibition reduces L-DOPA-induced dyskinesias in parkinsonian nonhuman primates"],"prefix":"10.1016","volume":"392","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5711-8929","authenticated-orcid":false,"given":"Brik A.","family":"Kochoian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3770-5461","authenticated-orcid":false,"given":"Stefano","family":"Coletta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huachen","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cassandra","family":"Bure","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rene","family":"Onrust","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Gaitanaris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Greg","family":"Demopulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stella M.","family":"Papa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"suppl 10","key":"10.1016\/j.jpet.2025.103760_bib1","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S1471-1931(00)00031-8","article-title":"Levodopa motor complications in Parkinson's disease","volume":"23","author":"Obeso","year":"2000","journal-title":"Trends Neurosci"},{"issue":"12","key":"10.1016\/j.jpet.2025.103760_bib2","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1474-4422(21)00249-0","article-title":"Amantadine in the treatment of Parkinson's disease and other movement disorders","volume":"20","author":"Rascol","year":"2021","journal-title":"Lancet Neurol"},{"issue":"5","key":"10.1016\/j.jpet.2025.103760_bib3","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/ana.410390504","article-title":"The response to levodopa in Parkinson's disease: imposing pharmacological law and order","volume":"39","author":"Nutt","year":"1996","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jpet.2025.103760_bib4","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/bs.pbr.2021.01.032","article-title":"Serotonin\/dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesia: an update","volume":"261","author":"Corsi","year":"2021","journal-title":"Prog Brain Res"},{"issue":"24","key":"10.1016\/j.jpet.2025.103760_bib5","doi-asserted-by":"crossref","first-page":"5622","DOI":"10.1111\/bph.15275","article-title":"Rho kinase inhibitor fasudil reduces l-DOPA-induced dyskinesia in a rat model of Parkinson's disease","volume":"177","author":"Lopez-Lopez","year":"2020","journal-title":"Br J Pharmacol"},{"issue":"1672","key":"10.1016\/j.jpet.2025.103760_bib6","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2014.0184","article-title":"Levodopa-induced plasticity: a double-edged sword in Parkinson's disease?","volume":"370","author":"Calabresi","year":"2015","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"10.1016\/j.jpet.2025.103760_bib7","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0079-6123(10)83011-0","article-title":"Maladaptive striatal plasticity in L-DOPA-induced dyskinesia","volume":"183","author":"Cenci","year":"2010","journal-title":"Prog Brain Res"},{"issue":"2","key":"10.1016\/j.jpet.2025.103760_bib8","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1471-4159.2006.04124.x","article-title":"Post- versus presynaptic plasticity in L-dopa-induced dyskinesia","volume":"99","author":"Cenci","year":"2006","journal-title":"J Neurochem"},{"issue":"4","key":"10.1016\/j.jpet.2025.103760_bib9","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0166-2236(92)90355-C","article-title":"The neostriatal mosaic: multiple levels of compartmental organization","volume":"15","author":"Gerfen","year":"1992","journal-title":"Trends Neurosci"},{"issue":"5","key":"10.1016\/j.jpet.2025.103760_bib10","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/j.1460-9568.2008.06387.x","article-title":"Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms","volume":"28","author":"Giorgi","year":"2008","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.jpet.2025.103760_bib11","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.neuint.2014.10.004","article-title":"Levodopa-induced dyskinesias are associated with transient down-regulation of cAMP and cGMP in the caudate-putamen of hemiparkinsonian rats: reduced synthesis or increased catabolism?","volume":"79","author":"Sancesario","year":"2014","journal-title":"Neurochem Int"},{"issue":"23","key":"10.1016\/j.jpet.2025.103760_bib12","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.3390\/cells12232754","article-title":"Targeting striatal glutamate and phosphodiesterases to control L-dopa-induced dyskinesia","volume":"12","author":"Kochoian","year":"2023","journal-title":"Cells"},{"issue":"5","key":"10.1016\/j.jpet.2025.103760_bib13","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1002\/mds.27341","article-title":"A selective phosphodiesterase 10A inhibitor reduces L-dopa-induced dyskinesias in parkinsonian monkeys","volume":"33","author":"Beck","year":"2018","journal-title":"Mov Disord"},{"issue":"8","key":"10.1016\/j.jpet.2025.103760_bib14","doi-asserted-by":"crossref","first-page":"947","DOI":"10.3390\/ph15080947","article-title":"Phosphodiesterase 10A Inhibition Modulates the Corticostriatal Activity and L-DOPA-Induced Dyskinesia","volume":"15","author":"Guimaraes","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"issue":"6","key":"10.1016\/j.jpet.2025.103760_bib15","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.neuropharm.2010.05.004","article-title":"Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues","volume":"59","author":"Lakics","year":"2010","journal-title":"Neuropharmacology"},{"issue":"26","key":"10.1016\/j.jpet.2025.103760_bib16","doi-asserted-by":"crossref","first-page":"6995","DOI":"10.1523\/JNEUROSCI.0852-07.2007","article-title":"Critical involvement of cAMP\/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-dopa-induced dyskinesia","volume":"27","author":"Santini","year":"2007","journal-title":"J Neurosci"},{"key":"10.1016\/j.jpet.2025.103760_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109060","article-title":"Phosphodiesterase 9 inhibition prolongs the antiparkinsonian action of l-dopa in parkinsonian non-human primates","volume":"212","author":"Masilamoni","year":"2022","journal-title":"Neuropharmacology"},{"issue":"6","key":"10.1016\/j.jpet.2025.103760_bib18","doi-asserted-by":"crossref","first-page":"564","DOI":"10.5966\/sctm.2014-0277","article-title":"Phosphodiesterase 7 inhibition induces dopaminergic neurogenesis in hemiparkinsonian rats","volume":"4","author":"Morales-Garcia","year":"2015","journal-title":"Stem Cells Transl Med"},{"issue":"2","key":"10.1016\/j.jpet.2025.103760_bib19","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1007\/s12035-019-01745-z","article-title":"Phosphodiesterase 7 Regulation in cellular and rodent models of Parkinson's disease","volume":"57","author":"Morales-Garcia","year":"2020","journal-title":"Mol Neurobiol"},{"issue":"2","key":"10.1016\/j.jpet.2025.103760_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017240","article-title":"Phosphodiesterase 7 inhibition preserves dopaminergic neurons in cellular and rodent models of Parkinson disease","volume":"6","author":"Morales-Garcia","year":"2011","journal-title":"PLOS One"},{"issue":"28","key":"10.1016\/j.jpet.2025.103760_bib21","doi-asserted-by":"crossref","first-page":"6128","DOI":"10.1523\/JNEUROSCI.3180-20.2021","article-title":"Selective inhibition of phosphodiesterase 7 enzymes reduces motivation for nicotine use through modulation of mesolimbic dopaminergic transmission","volume":"41","author":"Ciccocioppo","year":"2021","journal-title":"J Neurosci"},{"issue":"5","key":"10.1016\/j.jpet.2025.103760_bib22","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1152\/jn.00910.2014","article-title":"Dopamine regulates distinctively the activity patterns of striatal output neurons in advanced parkinsonian primates","volume":"113","author":"Singh","year":"2015","journal-title":"J Neurophysiol"},{"issue":"1","key":"10.1016\/j.jpet.2025.103760_bib23","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1124\/jpet.107.125666","article-title":"Blockade of cannabinoid type 1 receptors augments the antiparkinsonian action of levodopa without affecting dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys","volume":"323","author":"Cao","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"10.1016\/j.jpet.2025.103760_bib24","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/ana.410390505","article-title":"Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys","volume":"39","author":"Papa","year":"1996","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.jpet.2025.103760_bib25","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jneumeth.2013.02.004","article-title":"Assessment of adverse effects of neurotropic drugs in monkeys with the \"drug effects on the nervous system\" (DENS) scale","volume":"215","author":"Uthayathas","year":"2013","journal-title":"J Neurosci Methods"},{"issue":"4","key":"10.1016\/j.jpet.2025.103760_bib26","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1212\/WNL.56.4.455","article-title":"A randomized, controlled trial of remacemide for motor fluctuations in Parkinson's disease","volume":"56","author":"Shoulson","year":"2001","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.jpet.2025.103760_bib27","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/mds.26659","article-title":"A phase 2A trial of the novel mGluR5-negative allosteric modulator dipraglurant for levodopa-induced dyskinesia in Parkinson's disease","volume":"31","author":"Tison","year":"2016","journal-title":"Mov Disord"},{"key":"10.1016\/j.jpet.2025.103760_bib28","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3389\/fnagi.2018.00262","article-title":"Effects of mGluR5 antagonists on Parkinson's patients with L-dopa-induced dyskinesia: a systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Wang","year":"2018","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.jpet.2025.103760_bib29","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.neubiorev.2018.02.007","article-title":"Phosphodiesterase inhibition and modulation of corticostriatal and hippocampal circuits: clinical overview and translational considerations","volume":"87","author":"Heckman","year":"2018","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.jpet.2025.103760_bib30","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1093\/brain\/awv219","article-title":"Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinson's disease","volume":"138","author":"Niccolini","year":"2015","journal-title":"Brain"},{"issue":"10","key":"10.1016\/j.jpet.2025.103760_bib31","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/mds.27733","article-title":"Comparison of phosphodiesterase 10A and dopamine transporter levels as markers of disease burden in early Parkinson's disease","volume":"34","author":"Pagano","year":"2019","journal-title":"Mov Disord"},{"issue":"2","key":"10.1016\/j.jpet.2025.103760_bib32","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1172\/JCI90132","article-title":"Chemogenetic stimulation of striatal projection neurons modulates responses to Parkinson's disease therapy","volume":"127","author":"Alcacer","year":"2017","journal-title":"J Clin Invest"},{"issue":"8","key":"10.1016\/j.jpet.2025.103760_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114483","article-title":"Excessive firing of dyskinesia-associated striatal direct pathway neurons is gated by dopamine and excitatory synaptic input","volume":"43","author":"Ryan","year":"2024","journal-title":"Cell Rep"},{"issue":"42","key":"10.1016\/j.jpet.2025.103760_bib34","doi-asserted-by":"crossref","first-page":"10460","DOI":"10.1523\/JNEUROSCI.2518-08.2008","article-title":"Distinct roles of PDE4 and PDE10A in the regulation of cAMP\/PKA signaling in the striatum","volume":"28","author":"Nishi","year":"2008","journal-title":"J Neurosci"},{"key":"10.1016\/j.jpet.2025.103760_bib35","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1146\/annurev-neuro-061010-113641","article-title":"Modulation of striatal projection systems by dopamine","volume":"34","author":"Gerfen","year":"2011","journal-title":"Annu Rev Neurosci"},{"key":"10.1016\/j.jpet.2025.103760_bib36","doi-asserted-by":"crossref","first-page":"5316","DOI":"10.1038\/ncomms6316","article-title":"Cell type-specific plasticity of striatal projection neurons in parkinsonism and L-DOPA-induced dyskinesia","volume":"5","author":"Fieblinger","year":"2014","journal-title":"Nat Commun"},{"issue":"30","key":"10.1016\/j.jpet.2025.103760_bib37","doi-asserted-by":"crossref","first-page":"7537","DOI":"10.1523\/JNEUROSCI.1176-08.2008","article-title":"Inversion of dopamine responses in striatal medium spiny neurons and involuntary movements","volume":"28","author":"Liang","year":"2008","journal-title":"J Neurosci"},{"issue":"8","key":"10.1016\/j.jpet.2025.103760_bib38","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s00702-018-1886-0","article-title":"On the neuronal circuitry mediating L-DOPA-induced dyskinesia","volume":"125","author":"Cenci","year":"2018","journal-title":"J Neural Transm (Vienna)"},{"issue":"2","key":"10.1016\/j.jpet.2025.103760_bib39","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s43440-020-00060-y","article-title":"Ameliorative effects of a phosphodiesterase 10A inhibitor, MR1916 on L-DOPA-induced dyskinesia in parkinsonian rats","volume":"72","author":"Arakawa","year":"2020","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.jpet.2025.103760_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2021.173183","article-title":"A novel phosphodiesterase 1 inhibitor reverses L-dopa-induced dyskinesia, but not motivation deficits, in monkeys","volume":"205","author":"Enomoto","year":"2021","journal-title":"Pharmacol Biochem Behav"},{"issue":"6","key":"10.1016\/j.jpet.2025.103760_bib41","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/mds.26159","article-title":"Amantadine extended release for levodopa-induced dyskinesia in Parkinson\u2019s disease (EASED Study)","volume":"30","author":"Pahwa","year":"2015","journal-title":"Mov Disord"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525402730?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525402730?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T01:01:10Z","timestamp":1773882070000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356525402730"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":41,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0022356525402730"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103760","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phosphodiesterase 7 inhibition reduces L-DOPA-induced dyskinesias in parkinsonian nonhuman primates","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103760","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103760"}}